Genentech bets big on US soil amid policy storm

As pricing pressures and political headwinds reshape the pharma landscape, Genentech is doubling down on American manufacturing. The Roche subsidiary will pour over $700m into a major new facility in North Carolina—its first on the East Coast—supporting the metabolic medicines portfolio and adding hundreds of permanent jobs. It’s part of a broader $50bn US investment strategy aimed at shoring up operations as the Trump administration pushes for onshore production and introduces bold drug pricing reforms.

Yet the policy backdrop is far from stable. With the White House backing “most-favoured-nation” pricing tied to overseas rates, Roche has hinted that its investment plans could shift. For now, it’s staying the course—despite calls from federal officials to reconsider.

This signals a defining moment for pharma leaders: rethink global supply chains, reassess domestic exposure, and prepare for regulatory unpredictability that could rewrite the economics of blockbuster drugs.

Read the full breakdown →